Tscan therapeutics announces presentation at the 11th annual svb leerink global healthcare conference

Waltham, mass., feb. 10, 2022 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a biopharmaceutical company focused on the development of t-cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced that the company will present virtually at the 11th annual svb leerink global healthcare conference on friday, february 18, 2022, at 12:00 p.m. eastern time.
TCRX Ratings Summary
TCRX Quant Ranking